News >

Sartor Discusses Expanded Radium-223 Program, STAMPEDE Data in Prostate Cancer

Laura Panjwani
Published: Tuesday, Oct 27, 2015

Oliver Sartor, MD

Oliver Sartor, MD

Two recent trials—the expanded access program (EAP) following the ALSYMPCA trial and the STAMPEDE trial—provided critical insight for prostate cancer treatment, according to Oliver Sartor, MD, medical director of Tulane Cancer Center. However, both trials leave some questions unanswered, he adds.

Radium-223 was shown to be safe and well tolerated, regardless of prior or concurrent exposure to abiraterone and/or enzalutamide. However, it not yet understood if an earlier setting of abiraterone and/or enzalutamide and radium-223 would be more beneficial, said Sartor.

The STAMPEDE trial, which was the largest randomized prostate cancer clinical trial ever conducted, investigated the addition of docetaxel to standard hormonal therapy in men with newly diagnosed, hormone-naïve advanced prostate cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x